Abiopharma

NeuroSense Issues CEO Letter to Shareholders

MHS Serves Announces Recipients of over $2 Million Investment in Hoosier Employment

Werner® Earns Double Industry Honors for Outstanding Support of Military Veterans and Families

NeuroSense Issues CEO Letter to Shareholders

Clinical trial NCT07157423 updates: 1. completion date: 2027-03-26 → 2027-08-26 2. primary completion date: 2027-03-26 → 2027-08-26

Clinical trial NCT07220954 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. completion date: 2027-04-01 → 2027-05-21 3. primary completion date: 2026-09-09 → 2026-09-17 4. enrollment: 21 → 19 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT05176639: start date: 2021-12-03 → 2022-11-16.

Clinical trial NCT07000110: enrollment: 3195 → 3506 participants.

Clinical trial NCT03814746: enrollment: 255 → 254 participants.

Clinical trial NCT06677892 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. enrollment: 75 → 66 participants 3. enrollment type: ESTIMATED → ACTUAL